Should FDA Relax Phase I Percutaneous Valve Trial Enrollment Criteria?
This article was originally published in The Gray Sheet
Executive Summary
Pivotal clinical trials for percutaneous aortic or mitral valve repair should have two-year follow-up, rather then the one-year preferred by device firms, according to CDRH Cardiovascular Devices Branch Chief Bram Zuckerman, MD
You may also be interested in...
Tissue Valve Firms Target Younger Patients, Want Guidelines To Match
Tissue-based heart valve manufacturers are pushing to expand the treatment population for their products to include younger individuals
Tissue Valve Firms Target Younger Patients, Want Guidelines To Match
Tissue-based heart valve manufacturers are pushing to expand the treatment population for their products to include younger individuals
Edwards Foresees Percutaneous Heart Valve Replacement Milestones In 2006
Edwards Lifesciences expects to complete enrollment in the U.S. feasibility study for its Cribier-Edwards minimally invasive aortic heart valve during the first half of 2006